Table 4.

Multivariable delayed entry cox-proportional hazards models describing soy isoflavone intake and breast cancer recurrence, stratified by hormone receptor status and tamoxifen use^a

	ER− and PR −				ER+ or PR+				P valueb	Never Tamoxifen				Ever Tamoxifen				P valueb
	(n=287, 43 events)				(n=1551, 223 events)					(n=410, 61 events)				(n=1443, 209 events)
	n	HR	95% CI		n	HR	95% CI			n	HR	95% CI		n	HR	95% CI
Daidzein Intake (mcg/day)
0	67	1.00	Reference		349	1.00	Reference			92	1.00	Reference		327	1.00	Reference
0.10–7.77	54	1.69	0.73	3.91	257	1.08	0.72	1.63		68	1.63	0.72	3.68	244	1.12	0.75	1.69
7.78–149.59	54	0.96	0.36	2.53	320	0.86	0.57	1.28		80	1.31	0.58	2.99	296	0.78	0.52	1.19
149.60–1453.00	55	0.73	0.26	2.03	308	1.01	0.68	1.50		79	0.93	0.39	2.22	290	1.00	0.67	1.50
1453.10–9596.54	37	0.36	0.08	1.69	247	0.76	0.48	1.23		60	0.69	0.23	2.08	224	0.73	0.45	1.20
≥ 9596.55	20	1.45	0.43	4.95	70	0.82	0.40	1.68		31	2.40	0.93	6.18*	62	0.48	0.19	1.21
p for trend				0.38				0.29	0.56				0.69				0.10	0.24
Genistein Intake (mcg/day)
0	67	1.00	Reference		349	1.00	Reference			92	1.00	Reference		327	1.00	Reference
0.10–6.99	60	1.72	0.75	3.94	278	1.00	0.66	1.51		73	1.70	0.76	3.79	267	1.02	0.68	1.54
7.00–220.61	45	0.81	0.27	2.38	301	0.93	0.62	1.39		69	1.25	0.53	2.95	277	0.86	0.57	1.31
220.62–2,184.8	58	0.83	0.31	2.21	306	0.99	0.66	1.47		86	0.96	0.41	2.22	285	0.99	0.66	1.48
2,199.82–13, 025.87	36	0.38	0.08	1.79	247	0.77	0.48	1.24		59	0.70	0.23	2.10	224	0.74	0.45	1.21
≥ 13,025.88	21	1.34	0.39	4.57	70	0.83	0.40	1.69		31	2.42	0.95	6.21	63	0.48	0.19	1.22
p for trend				0.38				0.35	0.52				0.72				0.13	0.25
Glycetin Intake (mcg/day)
0–3.61	63	1.00	Reference		315	1.00	Reference			83	1.00	Reference		299	1.00	Reference
3.62–8.16	57	0.31	0.11	0.81	300	1.22	0.83	1.81		79	0.32	0.13	0.78**	279	1.26	0.85	1.87
8.17–14.99	57	0.23	0.07	0.73	311	0.81	0.53	1.25		77	0.26	0.10	0.73**	295	0.82	0.53	1.26
15.00–78.53	57	0.89	0.38	2.09	308	0.73	0.46	1.15		84	0.83	0.40	1.74	286	0.69	0.43	1.10
78.54–795.39	34	0.32	0.09	1.19*	243	0.87	0.54	1.41		58	0.87	0.37	2.01	219	0.77	0.46	1.28
≥ 795.40	19	0.38	0.08	1.79	73	0.94	0.47	1.89		29	0.68	0.22	2.12	64	0.85	0.40	1.80
p for trend				0.29				0.17	0.04				0.82				0.05	0.03

^aAll models were adjusted for soy supplement use, BMI 1 year before diagnosis, tobacco pack-years, tumor stage, menopausal status, age, race, and kilocalories.

^bP-value for interaction.

^*p ≤ 0.10

^**p ≤ 0.05